Anixa Biosciences Announces Treatment of Second Patient in the Fifth Cohort of its Ovarian Cancer CAR-T Clinical Trial
PR Newswire•01/10/2026•08:35 ET
0
Key Highlights
- ➤Second patient treated in Anixa Biosciences' (ANIX) fifth ovarian cancer CAR-T cohort
- ➤Cohort 5 dose 1×10⁷ CAR-positive cells/kg after lymphodepletion
- ➤No dose-limiting toxicities observed through first patient in Cohort 5
- ➤Four patients surpassed one-year survival, including one surviving approximately 28 months
Expert Statements
Amit Kumar, Chairman and CEO of Anixa Biosciences
“Ovarian cancer remains one of the deadliest cancers affecting women, and patients with recurrent disease face limited treatment options and poor outcomes. While this Phase 1 study is primarily designed to evaluate safety, we are highly encouraged that multiple patients have surpassed one year of survival following treatment, with one patient having survived beyond two years. Typically, these highly pre-treated patients survive a matter of weeks. We look forward to further evaluating this novel solid tumor-specific CAR-T therapy as enrollment progresses.”
Anixa Biosciences Announces Treatment of Second Patient in the Fifth Cohort of its Ovarian Cancer CAR-T Clinical Trial PR Newswire
Multiple Patients Surviving More Than One Year, Including One Beyond Two Years, With No Dose-Limiting Toxicities Observed to Date
Get started
Create a free account to read the full story.